Literature DB >> 26451298

Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma.

Sneha Berry1, Janis M Taube2.   

Abstract

Oncogenic driver mutations in several tumor types promote constitutive PD-L1 expression, a crucial ligand in PD-1-mediated tumor immune escape. Our studies in melanoma suggest a different mechanism-one of "adaptive immune resistance" in which PD-L1 expression is primarily driven by cytokine induction and is independent of BRAF mutational status.

Entities:  

Keywords:  BRAF; PD-L1; TIL; adaptive immune resistance; melanoma

Year:  2015        PMID： 26451298      PMCID： PMC4589064          DOI： 10.1080/2162402X.2015.1029704

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

2.  PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival.

Authors:  Evan J Lipson; Jeremy G Vincent; Myriam Loyo; Luciane T Kagohara; Brandon S Luber; Hao Wang; Haiying Xu; Suresh K Nayar; Timothy S Wang; David Sidransky; Robert A Anders; Suzanne L Topalian; Janis M Taube
Journal:  Cancer Immunol Res       Date:  2013-07       Impact factor: 11.151

3.  Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

Authors:  James S Wilmott; Georgina V Long; Julie R Howle; Lauren E Haydu; Raghwa N Sharma; John F Thompson; Richard F Kefford; Peter Hersey; Richard A Scolyer
Journal:  Clin Cancer Res       Date:  2011-12-12       Impact factor: 12.531

4.  Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.

Authors:  Janis M Taube; Alison Klein; Julie R Brahmer; Haiying Xu; Xiaoyu Pan; Jung H Kim; Lieping Chen; Drew M Pardoll; Suzanne L Topalian; Robert A Anders
Journal:  Clin Cancer Res       Date:  2014-04-08       Impact factor: 12.531

5.  Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.

Authors:  Janis M Taube; Robert A Anders; Geoffrey D Young; Haiying Xu; Rajni Sharma; Tracee L McMiller; Shuming Chen; Alison P Klein; Drew M Pardoll; Suzanne L Topalian; Lieping Chen
Journal:  Sci Transl Med       Date:  2012-03-28       Impact factor: 17.956

6.  PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.

Authors:  Nemanja Rodić; Robert A Anders; James R Eshleman; Ming-Tseh Lin; Haiying Xu; Jung H Kim; Katie Beierl; Shuming Chen; Brandon S Luber; Hao Wang; Suzanne L Topalian; Drew M Pardoll; Janis M Taube
Journal:  Cancer Immunol Res       Date:  2014-11-04       Impact factor: 11.151

7.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.

Authors:  Andrew T Parsa; James S Waldron; Amith Panner; Courtney A Crane; Ian F Parney; Jeffrey J Barry; Kristine E Cachola; Joseph C Murray; Tarik Tihan; Michael C Jensen; Paul S Mischel; David Stokoe; Russell O Pieper
Journal:  Nat Med       Date:  2006-12-10       Impact factor: 53.440

8.  Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

Authors:  Mohammad Atefi; Earl Avramis; Amanda Lassen; Deborah J L Wong; Lidia Robert; David Foulad; Michael Cerniglia; Bjoern Titz; Thinle Chodon; Thomas G Graeber; Begonya Comin-Anduix; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2014-05-08       Impact factor: 12.531

9.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962
  9 in total
  8 in total

1.  Variability of PD-L1 expression in mastocytosis.

Authors:  Ellen W Hatch; Mary Beth Geeze; Cheyenne Martin; Mohamed E Salama; Karin Hartmann; Gregor Eisenwort; Katharina Blatt; Peter Valent; Jason Gotlib; Ji-Hyun Lee; Lu Chen; Heather H Ward; Diane S Lidke; Tracy I George
Journal:  Blood Adv       Date:  2018-02-13

2.  PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status.

Authors:  Allison M Martin; W Robert Bell; Ming Yuan; Lauren Harris; Bradley Poore; Antje Arnold; Elizabeth L Engle; Laura Asnaghi; Michael Lim; Eric H Raabe; Charles G Eberhart
Journal:  J Neuropathol Exp Neurol       Date:  2020-01-01       Impact factor: 3.148

Review 3.  PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.

Authors:  Michal Šmahel
Journal:  Int J Mol Sci       Date:  2017-06-21       Impact factor: 5.923

4.  Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.

Authors:  Xinyue Wang; Lianjing Cao; Shouying Li; Fan Wang; Dingzhi Huang; Richeng Jiang
Journal:  J Cancer       Date:  2019-10-22       Impact factor: 4.207

Review 5.  Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy.

Authors:  Yu Yuan; Abdalla Adam; Chen Zhao; Honglei Chen
Journal:  Cancers (Basel)       Date:  2021-02-07       Impact factor: 6.639

6.  Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma.

Authors:  Fereshteh Ameli; Elham Shajareh; Maral Mokhtari; Farid Kosari
Journal:  BMC Cancer       Date:  2022-08-03       Impact factor: 4.638

7.  The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.

Authors:  Anna Tosi; Beatrice Parisatto; Paolo Boscolo-Rizzo; Antonio Rosato; Anna Menegaldo; Giacomo Spinato; Maria Guido; Annarosa Del Mistro; Rossana Bussani; Fabrizio Zanconati; Margherita Tofanelli; Giancarlo Tirelli
Journal:  J Exp Clin Cancer Res       Date:  2022-09-20

8.  Reactive versus Constitutive: Reconcile the Controversial Results about the Prognostic Value of PD-L1 Expression in cancer.

Authors:  Dapeng Hao; Guangyu Wang; Weiwei Yang; Jinan Gong; Xingmin Li; Mingming Xiao; Lijie He; Li Wang; Xiaobo Li; Lijun Di
Journal:  Int J Biol Sci       Date:  2019-07-21       Impact factor: 6.580
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.